RGEN Repligen Corp

Price (delayed)

$250.46

Market cap

$13.9B

P/E Ratio

86.97

Dividend/share

N/A

EPS

$2.88

Enterprise value

$13.72B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
The company's net income has surged by 60% YoY and by 9% QoQ
RGEN's EPS has surged by 56% year-on-year and by 9% since the previous quarter
The debt has grown by 36% YoY and by 6% from the previous quarter
RGEN's quick ratio is down by 33% year-on-year

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
55.49M
Market cap
$13.9B
Enterprise value
$13.72B
Valuations
Price to earnings (P/E)
86.97
Price to book (P/B)
7.69
Price to sales (P/S)
17.83
EV/EBIT
67.98
EV/EBITDA
55.6
EV/Sales
17.62
Earnings
Revenue
$778.77M
EBIT
$201.79M
EBITDA
$246.75M
Free cash flow
$41.48M
Per share
EPS
$2.88
Free cash flow per share
$0.75
Book value per share
$32.57
Revenue per share
$14.05
TBVPS
$22.88
Balance sheet
Total assets
$2.44B
Total liabilities
$639.55M
Debt
$416.68M
Equity
$1.81B
Working capital
$552.47M
Liquidity
Debt to equity
0.23
Current ratio
2.3
Quick ratio
1.69
Net debt/EBITDA
-0.73
Margins
EBITDA margin
31.7%
Gross margin
58.1%
Net margin
20.5%
Operating margin
26.4%
Efficiency
Return on assets
6.8%
Return on equity
9.1%
Return on invested capital
36.6%
Return on capital employed
10%
Return on sales
25.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
1.7%
1 week
17.83%
1 month
42.71%
1 year
-0.08%
YTD
-5.43%
QTD
54.22%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$778.77M
Gross profit
$452.61M
Operating income
$205.79M
Net income
$159.43M
Gross margin
58.1%
Net margin
20.5%
The operating income has soared by 67% YoY and by 8% from the previous quarter
The company's net income has surged by 60% YoY and by 9% QoQ
The revenue has soared by 53% YoY and by 6% from the previous quarter
RGEN's gross profit has soared by 51% YoY and by 4.7% QoQ

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
86.97
P/B
7.69
P/S
17.83
EV/EBIT
67.98
EV/EBITDA
55.6
EV/Sales
17.62
RGEN's EPS has surged by 56% year-on-year and by 9% since the previous quarter
The stock's P/E is 32% below its 5-year quarterly average of 125.1 and 9% below its last 4 quarters average of 93.5
The P/B is 48% more than the 5-year quarterly average of 5.1 and 6% more than the last 4 quarters average of 7.1
Repligen's equity has increased by 13% YoY and by 2.2% QoQ
The revenue has soared by 53% YoY and by 6% from the previous quarter
RGEN's P/S is 6% below its last 4 quarters average of 18.6 but 2.5% above its 5-year quarterly average of 17.1

Efficiency

How efficient is Repligen business performance
The return on equity rose by 32% year-on-year and by 7% since the previous quarter
RGEN's ROA is up by 24% year-on-year and by 4.6% since the previous quarter
The ROIC has contracted by 8% from the previous quarter
RGEN's return on sales is up by 8% year-on-year

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
The total liabilities has soared by 55% YoY and by 3.6% from the previous quarter
RGEN's quick ratio is down by 33% year-on-year
The debt is 77% less than the equity
The debt has grown by 36% YoY and by 6% from the previous quarter
Repligen's debt to equity has increased by 21% YoY and by 4.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.